ライフサイエンスコーパス: complete resection

1 damage evaluation ranging from 0.0 to 10.0 (complete resection).

2 ations ranging from 0.0 (no lesion) to 10.0 (complete resection).

3 Twenty patients (48%) received a primary complete resection.

4 6%) of 91 patients had a SN identified and a complete resection.

5 s of metastases, and the ability to obtain a complete resection.

6 ival and increased likelihood of achieving a complete resection.

7 ze and multiorgan involvement that precludes complete resection.

8 plete resection, and three others also had a complete resection.

9 tic factors are stage and ability to achieve complete resection.

10 19, 2018, 1280 patients were enrolled after complete resection.

11 regeneration of camera-type eyes even after complete resection.

12 otomy was performed when necessary to attain complete resection.

13 olved as an effective method for macroscopic complete resection.

14 mas (LGGs) in areas of the brain amenable to complete resection.

15 ibutable to metastatic disease undetected at complete resection.

16 asive carcinoma, they should be treated with complete resection.

17 ifteen of the sixteen tumors were successful complete resection.

18 cer (NSCLC) have a poor prognosis even after complete resection.

19 idual viable tumor and only three achieved a complete resection.

20 1.8%) died postoperatively, and 83 (76%) had complete resection.

21 , compared to non-seizure-free patients with complete resections.

22 superiority of iMRI over 5-ALA for achieving complete resections.

23 Of the 56 patients who underwent complete resection, 34 (61%) had gastrointestinal stroma

24 However, despite complete resection, 5-year survival rates have been disa

25 Fourteen sequences showing complete resection according to the 5-ALA technique coul

26 Twenty-one experimental sequences showing complete resection according to the 5-ALA technique were

27 otal of 1616 patients with a microscopically complete resection (according to local pathologists), in

28 and mortality were compared across 3 groups: complete resection achieved en-bloc (CR-EB), complete re

29 complete resection achieved en-bloc (CR-EB), complete resection achieved non-en-bloc (CR-NEB), and IR

30 o be tumor-free had no events; those who had complete resections achieved a 5-year EFS of 83% (SD = 6

31 nal EMR procedure provides low chance of R0 (complete resection) achievement in gastrointestinal NETs

32 ry cardiac tumors appear to benefit from the complete resection afforded by cardiectomy and transplan

33 previously treated, 47% were able to undergo complete resection after combined HAI and systemic thera

34 Likelihood of complete resection after recurrence (all sites) increase

35 is necessary to determine the likelihood of complete resection although debulking surgery often is b

36 of oral IEN varies from watchful waiting to complete resection, although complete resection does not

37 radiation plus surgery, yields a 50% rate of complete resection and a 30% 5-year survival.

38 ients with pathologic N2 NSCLC who underwent complete resection and adjuvant chemotherapy from 2006 t

39 For patients with N2 NSCLC after complete resection and adjuvant chemotherapy, modern POR

40 nts with diffuse PM who achieved macroscopic complete resection and had sufficient information on tum

41 ession-free survival rate was better after a complete resection and in older patients.

42 For the 45 patients undergoing complete resection and IOERT, the 5-year actuarial local

43 ents who underwent hepatectomy for CRLM with complete resection and known BRAF status during 2001 to

44 who underwent hepatectomy for CRLM, 1497 had complete resection and known BRAF status.

45 ed with our earlier experience, the rates of complete resection and overall survival have improved.

46 easible and is associated with high rates of complete resection and pathologic CR in both T3 and T4 t

47 Even after complete resection and radiation, relapse rates are high

48 Secondary outcomes were complete resection and recurrence at first surveillance

49 hat long-term survival was associated with a complete resection and the preoperative staging strategy

50 eatment option for stage IB-IIIA NSCLC after complete resection and, when recommended, adjuvant chemo

51 Fifty-one patients undergoing complete resection and/or ablation for colorectal hepati

52 44.7+), two had no residual disease found at complete resection, and three others also had a complete

53 ival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with

54 erum alpha-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky

55 Men with a complete resection at pcRPLND and <10% viable cells have

56 xtirpation via either en-bloc or non-en-bloc complete resection based on FS analysis is associated wi

57 Nephrectomy may be needed to achieve complete resection, but has no measurable influence on d

58 529 patients with epithelioid MPM underwent complete resection by EPP as part of a multimodality str

59 s in prognosis and outcome in patients after complete resection by examining a large cohort of STS pa

60 ction should be performed in patients when a complete resection can be realistically obtained and whe

61 scularis propria layer and larger than 2 cm, complete resection can be successfully performed without

62 Complete resections, defined as a residual tumor <=0.175

63 , but when executed, Artemis is essential to complete resection-dependent c-NHEJ.

64 n over-the-scope device offers the option of complete resection despite scar formation.

65 hful waiting to complete resection, although complete resection does not prevent oral cancer in high-

66 actively utilized for tumor localization and complete resection during surgery.

67 Efforts are needed to ensure complete resection, especially of larger lesions.

68 surgeon remains the cornerstone of safe and complete resection for adrenal malignant disease.

69 tive database of 1776 patients who underwent complete resection for CRLM at a single institution was

70 cranial irradiation in patients who undergo complete resection for early-stage small-cell lung cance

71 y the survival of 557 patients who underwent complete resection for HCC at four centers was examined.

72 tive radiation or chemoradiation followed by complete resection for locally advanced rectal cancer de

73 tion as well as increasing the likelihood of complete resection for pituitary tumours and gliomas.

74 ven advantage to adjuvant chemotherapy after complete resection for specific stage groups, new techni

75 Patients treated with complete resection had a median survival of 33 months an

76 ual analysis of (18)F-FET PET scans revealed complete resection in 16 of 43 patients and incomplete r

77 ntraoperatively resulted in a radiologically complete resection in 24 (80%) of 30 patients.

78 Surgery consisted of complete resection in 62 (69.7%) patients, partial resec

79 Only patients undergoing complete resection in high-volume centers without extrah

80 Lung ART evaluated 3D conformal PORT after complete resection in patients who predominantly had bee

81 with pathologic T1-2N0M0 SCLC who underwent complete resection in the National Cancer Data Base from

82 The impact of complete resection in this well-selected group is contro

83 Before chemotherapy, complete resection, incomplete resection, and biopsy or

84 , local recurrence following macroscopically-complete resection is common and a significant cause of

85 Recurrence of stromal tumors following complete resection is common in Carney's syndrome and pr

86 However, LGGs located in areas where complete resection is not possible can threaten both fun

87 Complete resection is required for cure.

88 Complete resection is the treatment of choice for most p

89 gression and adverse outcomes in cases where complete resection is unachievable.

90 Diagnosis was based on complete resection (n = 20), biopsy (n = 42), or clinica

91 r CSS of 79% versus 36% for patients without complete resection (n = 30; P < .0001).

92 PORT to no PORT in patients with NSCLC with complete resection, nodal exploration, and cytologically

93 had at least one local recurrence following complete resection of a primary retroperitoneal liposarc

94 Of these, 52 patients underwent complete resection of a single node.

95 A 55-year-old Caucasian female underwent complete resection of a stage IVA B3 thymoma.

96 s, complete resection of structural lesions, complete resection of abnormal electrocorticographic are

97 Complete resection of all gross residual disease was ach

98 t-sided hemicolectomy is not indicated after complete resection of an appendiceal NET of 1-2 cm in si

99 nts (71%) with both unilateral-only IEDs and complete resection of baseline ECoG IEDs had an excellen

100 Unilateral IEDs on scalp EEG (P = .001) and complete resection of brain regions generating IEDs on b

101 logic findings in patients who had undergone complete resection of bronchial carcinoid tumors were as

102 Methods Patients who underwent a complete resection of CLM between 1992 and 2012 were inc

103 al of 2,368 consecutive patients underwent a complete resection of CLM, with a median follow-up of 55

104 overall survival (OS) in patients who had a complete resection of colorectal liver metastases (CLM).

105 ed for all patients who underwent an initial complete resection of colorectal liver metastases betwee

106 ional cohort of consecutive patients who had complete resection of colorectal liver metastases from t

107 A complete resection of congenital intrahepatic bile ducts

108 The primary end point was complete resection of contrast enhancement on early post

109 Patients aged 18 years or older with complete resection of cutaneous melanoma metastatic to l

110 n operative candidates who could not undergo complete resection of disease.

111 Why patients frequently recur after complete resection of early-stage lung cancer remains un

112 Complete resection of electrocorticographic and anatomic

113 Recurrence after complete resection of gastric adenocarcinoma usually occ

114 We hypothesized that complete resection of gastric GISTs using a combination

115 patients with primary disease who underwent complete resection of gross disease (n = 80), the 5-year

116 eral-only IEDs on preoperative scalp EEG and complete resection of IEDs on baseline ECoG are associat

117 s, relative risk = 0.31 [95% CI, 0.16-0.64]; complete resection of IEDs on baseline ECoG, relative ri

118 Ninety-six patients who underwent complete resection of liver metastases from colorectal c

119 Complete resection of liver metastases from sarcoma in s

120 literature have examined adjuvant HAI after complete resection of liver metastases.

121 simultaneous lung and liver transplantation, complete resection of lung cancer, and mediastinal lymph

122 fter completing high-dose therapy, underwent complete resection of lung metastases, and remains disea

123 ck cancer requires a careful balance between complete resection of malignancy and preservation of fun

124 result of both selection by chemotherapy and complete resection of metastatic disease.

125 GS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors.

126 In this study of patients with upfront, complete resection of node-positive esophageal adenocarc

127 The administration of adjuvant therapy after complete resection of non-small-cell lung cancer is cont

128 er, were able to have an MRI scan, and had a complete resection of one to three brain metastases (wit

129 the surgical cavity in patients who have had complete resection of one, two, or three brain metastase

130 umor-to-background signal for safer and more complete resection of pediatric tumors during surgery.

131 The complete resection of pituitary adenomas (PAs) is unlike

132 Local recurrence after complete resection of primary retroperitoneal liposarcom

133 6 (including six with liver transplants) had complete resection of primary tumor.

134 queried for patients who underwent upfront, complete resection of pT1-4N1-3M0 esophageal adenocarcin

135 ents without systemic metastasis and in whom complete resection of residual cancer can be performed,

136 Data on optimal adjuvant therapy after complete resection of small-cell lung cancer (SCLC) are

137 y (BRT) or no further therapy (no BRT) after complete resection of soft tissue sarcomas of the extrem

138 t brachytherapy improves local control after complete resection of soft tissue sarcomas.

139 The 25% rate of recurrence after complete resection of stage II colon cancer (CC) suggest

140 After patients had undergone complete resection of stage III cutaneous melanoma, we r

141 g per kilogram in patients who had undergone complete resection of stage III melanoma.

142 nivolumab plus relatlimab to nivolumab after complete resection of stage III/IV melanoma.

143 icipants were aged 18 years or older and had complete resection of stage IIIA (lymph node metastases

144 were at least 18 years of age and underwent complete resection of stage IIIA (lymph node metastases

145 Gray-white blurring on MRI, smaller lesions, complete resection of structural lesions, complete resec

146 ptimum treatment consisting of selective and complete resection of the causative tumour is necessay t

147 In glioma patients, complete resection of the contrast-enhancing portion is

148 Complete resection of the envelope of supporting tissues

149 A complete resection of the epileptogenic zone is required

150 Complete resection of the lesion was achieved in 44 pati

151 e operated under local anaesthesia by either complete resection of the lesion with primary closure, o

152 the primary tumor and at least a macroscopic complete resection of the metastatic lesions.

153 al in patients with a local recurrence after complete resection of the primary and rerecurrence after

154 on chemotherapy, 54.7% of patients underwent complete resection of the primary tumor, 30.6% underwent

155 appendiceal NET of 1-2 cm in size who had a complete resection of the primary tumour between Jan 1,

156 ctors associated with improved survival were complete resection of the tumor (P = 0.001), nonmetastat

157 r patients with hepatoblastoma, a timely and complete resection of the tumor is critical to the patie

158 bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction a

159 e objective of surgery was a macroscopically complete resection of the tumour mass with en-bloc organ

160 Of these patients, 61 underwent complete resection of their first local recurrence.

161 in survival rate for patients who underwent complete resection of their primary tumor compared with

162 y-eight patients were explored and underwent complete resection of their tumors.

163 f achieving a seizure-free outcome following complete resection of this area (p=0.008).

164 Multivariate logistic regression revealed complete resection of tissue manifesting electrocorticog

165 ay be used in image-guided surgery to ensure complete resection of tumor tissue.

166 5-aminolevulinic acid (5-ALA) for achieving complete resections of contrast enhancement in glioblast

167 Recurrences after complete resections of metastatic CRC remain frequent.

168 Achieving complete resection offers the best chance of survival.

169 e treatment but can only be achieved through complete resection or disconnection of the epileptogenic

170 a volume </= 64cm(3) (OR = 3.17, p = 0.034), complete resection (OR = 15.50, p = 0.0009), diencephali

171 sis, surgical treatment, mutilating surgery, complete resection, or survival were not associated with

172 In a multivariate analysis, age, complete resection, pathologic stage, and pneumonectomy,

173 is significantly influenced by patient age, complete resection, pathologic stage, and pneumonectomy.

174 is as independent adverse prognosticators in complete resection patients.

175 Grossly complete resection (R0 or R1) was performed in 26 (90%)

176 Macroscopically complete resection (R0 or R1) was performed in all 26 pa

177 (NAT) critically influenced microscopically complete resection (R0) rates and long-term outcomes for

178 ars, 18-69) were identified with macroscopic complete resection (R0, R1) of abdominal and retroperito

179 cant prognostic parameters for patients with complete resections (R0) following neoadjuvant radiochem

180 Complete resections (R0) were performed in 66 of 74 (89%

181 ifference in risk of serious adverse events, complete resection rate, or polyp recurrence.

182 Data are reviewed in terms of complete resection rates and disease-free survival so as

183 recurrence exerts significant influence over complete resection rates for recurrent disease.

184 radiographic response rates, pathologically complete resection rates, disease-free and overall survi

185 Complete resection remains the most effective and only p

186 Complete resection remains the only means for cure, and

187 Complete resection remains the only therapy that offers

188 f the surgery (lobectomy: S: 56%, CT-S: 60%, complete resection: S: 80%, CT-S: 82%).

189 Complete resection (stages I and II) was achieved in 32

190 confirmed in a subgroup of 29 patients with complete resections, suggesting these pathways may play

191 rest was to obtain long-term follow-up after complete resection to determine the recurrence rates bas

192 urvival rate of patients who did not undergo complete resection was 4%.

193 follow-up period for patients who underwent complete resection was 42 months (range, 1 to 194 months

194 r relapse-free survival for patients who had complete resection was 74% (65-83).

195 Complete resection was achieved in 86.5% of patients (n

196 Complete resection was performed in 17 patients, and ima

197 Secondary complete resection was possible in six of 10 patients wi

198 r cancer who had undergone a macroscopically complete resection (which includes liver resection, panc

199 isualization of solid tumors that can enable complete resections while sparing normal surrounding tis

200 rcinoma define patients who, if they undergo complete resection, will have 100% disease-free survival

201 ity indicator, was defined as a pathological complete resection with at least 15 retrieved lymph node

202 Improved survival after a complete resection with curative intent is often predict

203 primary or metastatic tumors of the liver is complete resection with evidence that an anatomic resect

204 unresectable colorectal-liver metastasis to complete resection with hepatic-arterial infusion plus s

205 Complete resection with negative histologic margins was

206 Achieving complete resection with negative margins is one of the m

207 al resection, the surgical goal always being complete resection with negative margins.

208 of surgical intervention in this scenario is complete resection with no gross residual disease.

209 Complete resection with no tumor within 1 mm of the rese

210 ly diagnosed glioblastoma shall aim for safe complete resections with 0 cm3 contrast-enhancing residu

211 vival was 44% for all patients and 54% after complete resection, with no difference between T3 and T4